Skip to main content

Table 1 Summary of Treatment Received for Patients in Case Series

From: Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Primary Diagnosis Systemic treatment received before ICI (best response, progression free survival) ICI received (best response, progression free survival) Systemic treatment received post ICI (best response, progression free survival)
Case 1 HCC (uninfected) Sorafenib (SD, 17.3 weeks) PD-1 inhibitor (PD, 6.9 weeks) Sorafenib (PR, 50.4 weeksb)
Case 2 HCC (Child-Pugh A Hepatitis B) Oncolytic vaccine and sorafeniba (PD, 11.7 weeks) FGFR inhibitor and PD-1 inhibitor (SD, 21.1 weeks) Lenvatinib (PR, 18.0 weeks) Ramucirumab (PR, 24.0 weeks) XELOX (PD, 4.0 weeks)
Case 3 HCC (Child-Pugh A Hepatitis B) None PD-L1 inhibitor (SD, 31.0 weeks) Sorafenib (PR, 14.7 weeks); Lenvatinib (PD, 7.0 weeks) Regorafenib (PD, 4.0 weeks)
Case 4 HCC (Child-Pugh A Hepatitis C) None PD-L1 inhibitor (SD, 12.2 weeks) Sorafenib (CR, 65.4 weeksb)
Case 5 HCC (Child-Pugh A Hepatitis B) None PD-L1 inhibitor CTLA-4 inhibitor (PD, 16.4 weeks) Lenvatinib (PR, 20.4 weeks) Pan-HER inhibitor (PD, 3.1 weeks) FGFR inhibitor (NE, 2.6 weeks)
Case 6 Rectal cancer FOLFOX-Cetuximab ➔ deGramont-Cetuximab (PR, 55.9 weeks) FOLFIRI-Bevacizumab (PR, 55.6 weeks) Regorafenib (NE) FOLFIRI/Pan-Her inhibitor (NE) TAS-102 (PD, 9.6 weeks) PD-1 inhibitor and MEK inhibitor (SD, 12.1 weeks) FOLFIRI and cetuximab (PR, 39.1 weeks) FOLFOX and panitumumab (NE)
  1. SD stable disease, PD progressive disease, PR partial response, NE not evaluated
  2. a Sorafenib started after completion of vaccine; duration of sorafenib: 4.7 weeks
  3. b Ongoing response as of 30 March 2019